| |
|
|
|
|
|
The CellSearch™ Circulating Tumor Cell (CTC) Kit is intended for the immunomagnetic selection, identification, and enumeration of CTCs of epithelial origin in whole blood.
Features Include:
Ready-to-use ferrofluid-based capture reagent and
immunofluorescent reagents for 16 complete tests
Preloaded reagent tray for easy loading onto
CellTracks® AutoPrep® System
Embedded data button in reagent holder to assist in
kit lot tracking and reagent use monitoring
Specially designed cartridges for optimal CTC isolation and analysis
Designed for use with the CellTracks® AutoPrep® System and the
CellTrack
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
The CellSearch™ CTC Control kit maintains quality control for reagents, instruments, and operator techniques.
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
A direct measure of HER2 total protein and functional homodimers compared to an indirect measure via gene amplification (FISH).
Seven to ten times more sensitive than HER2 IHC testing.
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
Genomic Health® develops oncogenomic services that enhance the management of cancer. The first testing service — Oncotype DX® Breast Cancer Assay — is now available for use in clinical practice to quantify the likelihood of breast cancer recurrence and predict benefit from chemotherapy for an individual patient
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
The Vysis probes for oncology, cytology, and pathology provide the following advantages:
Specific high-intensity signals without amplification and detection steps
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
SecurViewDX™ diagnostic workstations put the tools and workflow designed for the radiologist right at your fingertips. Now you can display and interpret digital mammograms from any vendor, locate regions of interest using sophisticated CAD tools and view current and prior mammograms alongside breast images from MRI, PET and ultrasound with seamless file sharing.
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
The SPOT-Light® HER2 CISH Kit utilizes Invitrogen’s chromogenic in situ hybridization (CISH) technology. The CISH technology enables the pathologist to evaluate HER2 gene expression in formalin-fixed, paraffin-embedded tissue sections using brightfield microscopy. HER2 CISH allows analysis of the genetic status of breast cancer cells within the context of tissue morphology.
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
Hologic's StereoLoc II was built on the technology platform developed for prone stereotactic applications. This common platform allows the StereoLoc II to provide the same image quality, targeting accuracy, flexibility in procedural options, image processing functions, and operational efficiencies.
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
Decreasing levels of Serum HER-2/neu (15 ng/ml) may indicate treatment response and disease stability
Increasing levels of Serum HER-2/neu (15 ng/ml) may indicate disease progression
Monitoring Serum HER-2/neu levels yields important information about response to therapy, and may help physicians make more informed decisions when developing and modifying patient treatment regimens (2-4)
|
Company:
Date:
December 01, 2008
|
|
|
|
|
|
|
|
|
|
HERmark™ Breast Cancer Assay is a CLIA-validated, quantitative assay, based on VeraTag™ technology, that measures HER2 total protein and HER2 homodimer levels. It is intended for use with formalin-fixed paraffinembedded (FFPE) tumor specimens
|
Company:
Date:
March 03, 2009
|
|
|
|
|